Brief: U.S. FDA awards Year Two funds to Palvella's Phase 3 Selva trial

Palvella Therapeutics

13/10/2025 12:40

Oct 13 (Reuters) - Palvella Therapeutics Inc PVLA.O:

U.S. FOOD AND DRUG ADMINISTRATION AWARDS YEAR TWO PROCEEDS FROM ORPHAN PRODUCTS GRANT SUPPORTING PALVELLA THERAPEUTICS’ PHASE 3 SELVA TRIAL OF QTORIN™ RAPAMYCIN FOR MICROCYSTIC LYMPHATIC MALFORMATIONS

PALVELLA THERAPEUTICS INC - TOP-LINE DATA FROM SELVA EXPECTED Q1 2026; NDA SUBMISSION H2 2026

Source text: ID:nGNX1jz5Rn

Further company coverage: PVLA.O

 (Reporting by Anhata Rooprai)

 ((Anhata.Rooprai@thomsonreuters.com;))